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The cell fate-determining roles played by members of the cyclin-dependent protein kinase 
(CDK) family explain why their dysregulation can promote proliferative diseases, and 
identify them as potential targets for drug discovery in oncology and beyond. After many 
years of research, the first efficacious CDK inhibitors have now been registered for clinical 
use in a defined segment of breast cancer. Research is underway to identify inhibitors with 
appropriate CDK-inhibitory profiles to recapitulate this success in other disease settings. 
Here we review the structural data that illustrates the interactions and properties that 
confer upon inhibitors affinity and/or selectivity towards different CDK family members.  
We conclude that where CDK inhibitors display selectivity, that selectivity derives from 
exploiting active site sequence peculiarities and/or from the capacity of the target CDK(s) 
to access conformations compatible with optimizing inhibitor-target interactions.   
Summary points 
• Type I, “1.5”, II and III inhibitors have been described for CDKs 
• Type I inhibitors engage the hinge through a range of hydrogen and/or halogen-
bonding motifs 
• CDKs have a bulky gatekeeper which can contribute to inhibitor binding or be 
manipulated to permit selective inhibition/co-factor utilization 
• Plastic rearrangements of the glycine lid may play a role in inhibitor selectivity by 
allowing read out of sequence differences remote from the active site 
• A “selectivity surface” adjacent to the ATP-binding site differs in character in 
different CDK subfamilies, and can be predictably targeted to provide a degree of 
selectivity 
• The C-terminal tail can contribute to inhibitor contacts in transcriptional CDKs 




Originally identified as regulators of the eukaryotic cell cycle, CDKs also regulate 
transcription and, in certain cell types, differentiation [1-3]. The activities of CDK family 
members impact several hallmarks of cancer [4]. In specific cellular settings, 
inappropriately elevated CDK activity, for example that of the cell cycle regulators CDK2, 
CDK4 and/or CDK6, has been identified as a cancer driver [5-8]. Expression or mutation of 
the activating cyclin subunit or decreased expression or mutation of an inhibitor (for 
example members of the INK family that bind specifically to CDK4 and CDK6) are 
frequently observed cancer-associated alterations (http://cancer.sanger.ac.uk/cosmic). 
CDKs  7, 8, 9, 11 and 20 regulate the synthesis of mRNA and therefore, by changing 
patterns of gene transcription, impact cell survival and differentiation [3, 9]. As a reflection 
of their differing roles in tissue physiology, aberrant activity of cell cycle or transcription 
regulatory CDKs can initiate or drive tumor progression in a cell-type specific manner, 
offering the opportunity to target specific cancers with CDK-selective inhibitors in certain 
patient populations. 
CDK active and inactive states 
A conserved feature of protein kinase activation is remodeling of an inactive monomeric 
kinase fold in response to protein association and /or post-translational modification [10, 
11]. The structure of monomeric CDK2 revealed how an inactive state derives from 
misalignment of residues required for productive substrate binding and catalysis [12]. 
Association with a cognate cyclin and, for most CDK-cyclin pairs, phosphorylation of a 
conserved threonine residue within the activation loop, are minimal pre-requisites for full 
activity [1, 13, 14]. However, the catalytically competent structure can be inferred to form 
only upon binding of ATP and peptide substrates: the conformation of the C-helix of CDK4 
in complex with cyclin D resembles that of inactive, monomeric CDK2, suggesting the 
need for further conformational change in the Michaelis complex to enable 
phosphotransfer (Figure 1a, b [15]). 
One challenge for drug development is that 20 members of the CMGC subfamily of the 
human kinome are sufficiently related to be classified as CDKs [3, 16]. Among these 
proteins, sequence identity is high within the residues that directly line the CDK active site 
(Figure 1c, d), and their convergence to a conserved structure upon activation has 
presented challenges for the design of inhibitors that target individual family members. 
Nevertheless, the available sequence diversity and conformational plasticity of the CDK 
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fold have together offered opportunities to derive potency and selectivity.  However, most 
inhibitor series exhibit substantial activity for a subset of the family.  
The most successful clinical approach to date has involved targeting CDK4 and CDK6 [8, 
17, 18]. This strategy exploits structural properties of CDK4 and CDK6 that distinguish 
them from the rest of the family: CDK4 bound to cyclin D and phosphorylated on the 
activation loop preserves “inactive” structural features observed in monomeric CDK2, 
suggesting a mechanism wherein only when both ATP and peptide substrate are engaged 
is the catalytically competent conformation formed ([19, 20]; Figure 1b).  
We will review how CDK structural biology has assisted the design of CDK inhibitors, 
highlighting structural properties that have been exploited to provide selectivity. 
Accordingly, we will limit our discussion to inhibitor series for which structures bound to the 
target CDK have been determined.  
The CDK ATP binding site  
Conformational change is an essential element of protein kinase function. It has been 
hypothesized that the conformations that have been observed in protein kinase-inhibitor 
complexes represent snapshots of states that might exist through the catalytic cycle [21]. 
Inhibitors that capture the kinase target in particular conformational states have been 
categorized as type I, II, III or IV depending on whether they mimic the interactions of ATP 
with a catalytically competent kinase active site (DFG-in, type I); occupy the ATP binding 
site and stabilize a catalytically inactive DFG-out conformation (type II); are non-
competitive with ATP and bind to an hydrophobic pocket adjacent to the ATP binding site 
(type III) or are allosteric (type IV), binding away from the ATP binding site [22].  
The first type I CDK inhibitors whose development was informed by structural biology were 
targeted against CDK2 (Table S1, [23]). These structures illustrated how inhibitor binding 
can (i) satisfy the hydrogen bonding potential of the backbone Glu81 carbonyl and Leu83 
amide moieties within the hinge sequence (which anchor the adenine N1 and N6 of ATP 
respectively), (ii) offer a planar moiety that mimics the adenine ring, (iii) fill the binding 
pocket to contact residues that do not contact ATP, and (iv) probe the ribose and 
phosphate binding sites (Figure 2).  
Dinaciclib (IC50 values against CDKs 1, 2, 5 and 9 of 3, 1, 1 and 4 nM respectively [8]) has 
undergone advanced phase III clinical trials and is currently being considered in 
combination therapies [24, 25]. The structure of dinaciclib bound to CDK2 illustrates the 
binding mode of this class of type I pan CDK inhibitor (Figure 2b, PDB 4KD1). It also 
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reveals the challenges of achieving selectivity within the highly-conserved ATP binding 
site: many of the residues that directly contact ATP are identical among CDKs.   
There are variations in the ways that adenine mimetics can bind to the hinge that links the 
N- and C-terminal lobes: 4-(1,3-Benzothiazol-2-yl)thiophene-2-sulfonamide (compound 4a, 
CDK5 IC50 551 nM) bound to CDK5-p25 makes a water-mediated interaction (PDB 4AU8, 
[26], Figure 2d), as does a series of 2, 4, 6-tri-substituted quinazolines that targets CDK2 
(CDK2-compound 51, PDB 2B53, CDK2 IC50 0.6 ± 0.1 uM, [27]). 6-aza-benzothiophene-
containing compounds targeting CDK8 (for example compound 22, IC50 CDK8 5.3 nM) 
form a single hydrogen bond to the hinge residue Ala100 (equivalent to CDK2 Leu83, PDB 
5CEI, [28], Figure 2e), whereas DRB (5,6-dichlorobenzimidazone-1-b-D-ribofuranoside), a 
CDK9-selective inhibitor (CDK9 IC50 230 nM [29]) exploits halogen bonds (PDBs 3MY1, 
4EC8, [29, 30], Figure 2f). The potential to make a third hydrogen bond to the backbone 
carbonyl equivalent of CDK2 Leu83 may be exploited to anchor and/or orientate the purine 
mimetic to optimize vectors to exploit sites beyond the adenine binding site (e.g. PDB 
entries 3DDQ and 1H1S, [31, 32], Figure 2c). Notably, although inhibitors make direct 
interactions with backbone moieties, sequence differences within the hinge appear to 
impact inhibitor potency and selectivity, presumably through effects on the relative 
orientations of the N- and C-terminal lobes and domain flexibility [33-35]. Such effects are 
difficult to rationalize, but are supported by results derived from CDK2 mutants in which 
the hinge sequence has been changed to that of CDK4 or CDK6 [36, 37].  
The	gatekeeper	pocket	
The CDK active site cleft is larger than is required for cofactor binding, and the additional 
space within the cleft has been widely exploited. At the back of the cleft, CDKs have a 
large gatekeeper residue (phenylalanine in all members except CDK10, 11A and 11B 
where it is a methionine) that can make multiple interactions. For example, edge-to-face 
aromatic-aromatic interactions are exploited in (i) a series of 4-anilinoquinazolines 
targeting CDK2 (PDB 1DI8, [38]), (ii) 7-azabenzimidazoles (e.g. CDK6-compound 3, PDB 
entry 4EZ5, IC50s vs CDK4/6 12 ± 2/300 ± 100 nM, >15 uM vs CDK1/6.2 ± 0.4 uM CDK2, 
[35], Figure 3a), and 4-(pyrazol-4-yl)-pyrimidines targeting CDK4/6 (e.g. CDK6-compound 
37 PDB 3NUP; IC50 CDK4-cyclin D1 12 ± 1 nM; [39]), and (iii) pyrido[4′,3′:4,5]pyrrolo[2,3-
d]pyrimidine derivatives characterized as dual FLT3/CDK4 inhibitors (e.g. CDK6-
compound 1, PDB 4TTH, FLT3 IC50 14 nM/CDK4-cyclin D1 IC50, 2 nM, [40]). 
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Favorable halogen-aromatic interactions are made in a quinazoline series that targets 
CDK2 (PDB 2B53, [27]), in the 4-(pyrazol-4-yl)-pyrimidines series mentioned above that 
targets CDK4/CDK6 (CDK6-compound 50 PDB 3NUX, CDK4-cyclin D1 IC50 11 nM; [39]), 
in CCT251545, that 
 
 targets CDK8, (PDB entry 5BNJ, [41]) and CCT251921, that targets CDK8 (IC50 2.3 ± 0.8 
nM) and CDK19 (IC50 2.6 ± 0.4 nM, PDB 5HBJ [42], Figure 3b). 
The sulfur atom of the thiadiazole scaffold in a CDK8-compound 6 structure (PDB 5ICP, 
CDK8 IC50 3.8 ± 1.9 nM [43], Figure 3c) has also been reported to interact with the 
phenylalanine sidechain. The thio-methylene moiety in a series of 2-amino-5-thioalkyl-
substituted thiazoles bound to CDK2 occupies a hydrophobic pocket to which Phe80 
contributes (PDB 4LYN, [44]. 
A preference for type I over type II inhibitors derives in part from the bulky character of the 
gatekeeper residue in CDKs. Mutation of this residue to a smaller amino acid allows 
access to the back pocket and has been used in conjunction with modified ATP or 
inhibitors to respectively identify CDK substrates and as a probe for CDK function [45, 46].  
Many inhibitor series build from this region to make either direct or water-mediated 
interactions with the conserved lysine-glutamate pair (Lys33 and Glu51 in CDK2) that 
coordinates the ATP alpha-phosphate group.  Filling this back part of the cleft with small, 
branched aromatic or halogen-rich moieties is common feature of a number of inhibitor 
series.  Notably larger moieties can flip the inhibitor binding mode offering alternative 
options for inhibitor design from a conserved scaffold.  
The	DFG	motif	and	back	pocket	remodeling	
The character of this region of the active site depends crucially on the DFG conformation 
[22, 47]. The first observation of a DFG out cyclin-bound CDK structure was that of CDK8 
bound to cyclin C and sorafenib (Figure 4a, PDB 3RGF [48]), a type II inhibitor of other 
protein kinases [49]. Starting from sorafenib, a series of CDK8 inhibitors stabilizing the 
DFG-out (DMG-out in CDK8) conformation were developed (e.g. CDK8-cyclin C-
compound 20, CDK8 IC50 17.4 nM, PDB 5HVY, [50]). CDK8 demonstrates flexibility in this 
part of the structure as apo-CDK8-cyclin C has a DMG-in structure (PDB 4F7S, [51]). A 
number of CDK8-cyclin C-type I inhibitor co-complexes have been reported, including 
CDK8-cyclin C bound to cortistatin A (PDB 4CRL, [52], Figure 4b) and a series of 
azabenzothiophene derivatives (PDB 5CEI, [28]. Reflecting their close phylogenetic 
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relationship, a number of type I inhibitors have been developed that are selective for CDK8 
and CDK19. These include CCT251545 (CDK8-Kd 2 nM, PDB 5BNJ, [41]), 2,8-
disubstituted-1,6-naphthyridine- and 4,6-disubstituted-isoquinoline-based ligands [53] and 
a series of compounds based on a 3-methyl-1H-pyrazolo[3,4-b]-pyridine scaffold (e.g. 
MSC2530818, CDK8 IC50 2.6 ± 0.1 nM, PDB 5IDN, [43]).  
Prolonging the engagement of an inhibitor with its target can lead to improved 
pharmacokinetic (PK) properties and greater efficacy [54, 55], and has been reported as a 
characteristic of type II protein kinase inhibitors that target tyrosine kinases [47]. However, 
within a set of inhibitors that elaborated a pyrazole urea based scaffold (PDBs 4F6S, 4F7J, 
4F70, 4F6U, 4F7N, 4F7L and 4F6W, [51]) residency time did not track with DMG 
conformation, but rather was hypothesized to derive from interactions with the hinge and 
the “selectivity surface” on the kinase C-terminal lobe. However, some PK optimization of 
CDK inhibitors has been rationalized by structural insights. Roniciclib (BAY 1000394) is a 
type I pan CDK inhibitor which exhibits kinetic selectivity for CDK2 and CDK9 [56]. CDK2 
showed a DFG loop adaptation as a response to the presence of a 5-(trifluoromethyl) 
substituent, but not of a hydrogen or bromine atom substitution (Compare PDBs 5IEV and 
5IEX). A distinguishing feature of the trifluoromethyl-substituted inhibitor-bound CDK2 
structure was the network of water molecules between the inhibitor moiety, the DFG motif 
and the gatekeeper, Phe80. The DFG conformation was distinct from the DFG-out 
conformation characteristic of other protein kinases, but had been previously observed in 
the CDK2-R547 structure (CDK2 Ki 1 nM, PDB 2FVD, [57]). 
The	ATP	ribose	phosphate	binding	pocket	
There are fewer reports of rational SAR where interactions offered by the ribose-
phosphate binding pocket have been targeted. This part of the active site is composed of a 
number of flexible loop regions (Figure 5a) making rational design difficult: molecular 
dynamics simulations conducted on CDKs and CDK-cyclin complexes have illustrated that 
the glycine-rich lid is highly dynamic in nature [58].  The determination of the structure of 
CDK5 bound to p25 (PDB 1H4L, [59]) revealed that its active site is very similar to that of 
CDK2. However, there is local restructuring upon both (R)-roscovitine (PDB 1UNL, [60]) 
and compound 1.0 binding (PDB 3O0G, [61]) to yield an unusual glycine-rich loop 
conformation, that presumably reflects the CDK5-specific aspects of the sequence in this 
region (Figure 5b). Similarly, binding of an aminopurine derivative bearing a bulky 
biphenyl substituent at the 6-position has been observed to stabilize a glycine-rich loop 
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conformation that is preferred in CDK2 (PDB 5LQE) and that has not been observed in 
CDK1 (PDB 5LQF) [62]. Though difficult to rationalize, the circa 2000-fold selectivity of this 
biphenyl derivative for CDK2 over CDK1 must derive from differences in conformational 
preferences supported by the CDK1 or CDK2 folds.  
Within a series of 4-(thiazol-5-yl)-2- (phenylamino)pyrimidine-5-carbonitriles, a comparison 
of inhibitor binding to CDK2 and CDK9 (E.g. compare binding of compound 12u, CDK2 
and CDK9 Kis of 568 nM and 7 nM and PDBs 4BCP and 4BCG respectively [63]) 
illustrates how, despite a broadly conserved binding pose, subdomain movements and 
local conformational flexibility around the CDK9 active site can drive compound selectivity 
(Figure 5c, [63, 64]). Comparing the structures of CDK9-cyclin T bound to a more diverse 
inhibitor set reveals that significant movements of the glycine-rich loop (and also of the 
beta3-alphaC loop) frequently accompany potent CDK9 inhibitor binding ([29, 65, 66], 
Figure 5d).	
The selectivity surface  
To discriminate more effectively between CDKs, the sequence differences immediately 
outside the active site on the surface of the C-terminal lobe can be probed by extending 
out from the purine binding site. This surface is quite different in character between 
CDK1/2 (PDBs 4YC3/1JST), CDK4/6 (PDBs 2W96/1JOW) and CDK8/9 (PDBs 
3RGF/3BLQ), (as shown in Figure 6: equivalent residues in other CDKs can be inferred by 
reference to Figure 1c). 
Various CDK4/6-selective inhibitor series exploit the surface, for example offering 
substituted piperazine moieties capable of favorable polar interactions with the hydroxyl 
side chain of CDK4 Thr102 or CDK6 Thr107, but being repulsed by the charge on CDK2 
Lys89 [40]. Palbociclib (PDB 2EUF, [34], Figure 6a) and ribociclib (PDB 5L2T, [67], 
Figure 6b) bound to monomeric CDK6 nicely illustrate how this surface can be exploited. 
Together with neighboring amino acids, the peptide chain around Lys89 shapes a groove 
that can be exploited to derive CDK1/2 selectivity. As examples, the 4’-sulfamoylanilino 
group present in NU6102 sits within this pocket and makes hydrogen bonds to the 
sidechain carboxylate and peptidic nitrogen of Asp84 (PDB entry 1H1S, [32], Figure 6c).  
CDK2 Lys89 has also been targeted by a covalent strategy [68].  The flexibility of the 
CDK9 sequence following the hinge accommodates the bulky, substituted aniline moieties 
that drives compound selectivity in a series of substituted 4-(thiazol-5-yl)-2-
(phenylamino)pyrimidine-5-carbonitriles (PDB entries 4BCF, 4BCH, 4BCI, 4BCJ, 4BCM, 
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4BCN, 4BCK, 4BCO, 4BCQ, [63, 64], Figure 6d).  Coupled to groups that probe sequence 
differences, the most successful compounds have identified a vector from the purine 
mimetic such that the conformation of the bound inhibitor is relatively strain-free and 
entropically favored because of pre-organization of the free ligand.    
CDK4/6 lend themselves to selective inhibition and show clear disease linkage 
CDK4 and CDK6 are the best validated CDK targets in the largest number of clinical 
settings [17].  Although no structures have been reported for such inhibitors bound to 
CDK4/6-cyclin D complexes, drug discovery programs have developed CDK4/6-selective 
inhibitors of which two, ribociclib [69] and palbociclib [33] are approved for the treatment of 
hormone receptor positive and human epidermal growth factor receptor-2 negative 
(HR+/HER2−) breast cancer. This success has been driven in part by the ability to identify 
patients where enhanced CDK4 or CDK6 activity is a driver of cancer progression 
(http://cancer.sanger.ac.uk/cosmic). It can also be hypothesized that the unusual plasticity 
of CDK4, and potentially also that of CDK6, allows the development of potent and 
selective inhibitors despite the high degree of sequence conservation within CDK active 
sites.  However, it is worth noting that the responses of CDK4 and CDK6 to cognate cyclin 
binding may differ. CDK4 does not adopt a fully active conformation upon cyclin D and 
activation segment phosphorylation (PDB 2W96, [20], whereas viral cyclin binding drives 
CDK6 to adopt an active conformation in which the activation segment is not 
phosphorylated but would be predicted to accommodate a peptide substrate (PDB 1JOW, 
[70]).  
In the absence of structures for inhibitors bound to active CDK4/6-cyclin D, it is difficult to 
rationalize inhibitor properties.  However, structures were used to guide optimization of a 
series of 4-(pyrazol-4-yl)-pyrimidines as CDK4/6 inhibitors using monomeric CDK6 as the 
template (E.g. CDK6-compound 50, CDK4-cyclin D1 IC50 11 nM, [39]). Structures of 
monomeric CDK6 bound to several clinical candidates have now been determined (PDB 
entries (5L2S, abemaciclib; 5L2W, dinaciclib; 5L2I, palbociclib; 5L2T, ribociclib, [67]). More 
detailed rationalization of their inhibitory properties awaits their structure determination 
bound to a CDK4/6-cyclin D complex.  
The C-terminal tail 
The transcriptional CDKs are characterized by extended C-terminal sequences beyond the 
conserved kinase domain. Though few inhibitor co-complex structures have been 
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determined for this transcriptional CDK sub-class, emerging data shows how the C-
terminal tail can impact the character of the ATP binding site. The CDK9 tail shapes the 
catalytic cleft and its conformational cycle results in an ordered binding of substrates and 
release of products (PDB 4EC8, [30]). It is exploited by the CDK9 inhibitor 5,6-
dichlorobenzimidazole 1-b-D-ribofuranoside (DRB) that is a more potent inhibitor of full-
length CDK9 than C-terminally truncated variants. DRB binding locks the CDK9 N- and C-
terminal lobes in an orientation that favors the ordering of the C-terminal sequence (Figure 
7a). Similar trapping of AMP-PNP in a closed state assisted by residues located within the 
C-terminal extension is observed in the structure of a CDK12-cyclin K-AMPPNP complex 
(PDBs 4NST, [71]; and 4CXA, [72]). Although there are no deposited structures for 
CDK13-cyclin K bound to ATP-competitive inhibitors, the CDK13 structure reveals a 
similar C-terminal helix that extends into the active site where it interacts with ATP (PDB 
5EFQ, [73]). The CDK8 C-terminal tail also reaches up into the active site and, in the 
presence of the ATP-competitive inhibitor CCT251545 (a 3,4,5-trisubstituted pyridine) 
makes a favorable cation-pi interaction between the phenyl ring of the inhibitor and the 
guanidine moiety of Arg356 (PDB 5BNJ,[41], Figure 7b). Indeed, representatives from 
diverse chemotypes have now been crystallized with CDK8-cyclin C and, irrespective of 
the orientation of the DMG sequence, significant interactions are made with the C-terminal 
tail sequence. 
CDK7, CDK12 and CDK13 contain cysteine residues within their extended C-terminal 
sequences. These residues offer the possibility of targeting by covalent inhibitors and, as 
they are outside the kinase core fold, achieving greater selectivity. THZ1 is a potent and 
selective chemical probe targeting CDK7 [74] and covalently interacts with Cys312, a 
residue that is not built in the CDK7 crystal structure (which terminates at Asn311, PDB 
1UA2, [75]). CDK12 and CDK13 have a cysteine residue within 4 residues of CDK7 
Cys312 and THZ1 does indeed inhibit CDK12 and CDK13 at higher concentrations [74]. 
The structure of the THZ531 bound to CDK12-cyclin K reveals the re-arrangements within 
the CDK12 C-terminal lobe that re-orients the cysteine sidechain (Cys1039) to permit the 
covalent interaction to form (PDB 5ACB, [76], Figure 7c). Indeed THZ (and derivatives) is 
proving to be a useful tool compound to delineate transcriptional CDK activity in defined 
cellular settings [76].  
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Targeting the monomeric enzyme  
Unconstrained by catalytic requirements, CDKs are more diverse in structure when 
monomeric than cyclin-bound and, correspondingly, show less well conserved patterns of 
inhibitor binding [77]. Such observations have prompted studies to identify type II and type 
III inhibitors that can stabilize monomeric CDKs in conformations that are incompatible 
with catalytic activity and/or cyclin binding.  
Most progress towards this aim has been made with CDK2. Although it was originally 
thought that CDK2 would not be amenable to adopting a DFG-out structure, judicious 
screening identified an aminopyrimidine-phenyl urea inhibitor (K03861) that stabilized such 
a conformation [78]. This conformation proved to be competitive with cyclin binding and to 
have a slow koff, i.e. to have characteristics consistent with a type III inhibitor.  
Moving away from the active site, high concentrations of 8-anilino-1-naphthalene sulfonate 
(ANS) can drive formation of a large pocket that accommodates two adjacent ANS 
molecules, extending from the DFG region to above the C-helix [79]. The shift in the C-
helix position was predicted to be incompatible with cyclin binding, a hypothesis confirmed 
by competitive binding studies (Figure 8a).  
In another approach, a high throughput screen has identified compounds that bound to 
inactive unphosphorylated monomeric CDK2 rather than phosphorylated CDK2-cyclin A. A 
type I.5 quinolone-based inhibitor (DFG-in, occupying the ATP-binding site and adjacent 
non-canonical pockets, compound 14) was subsequently developed with a Kd of 5 nM, 
determined using a temperature-dependent circular dichroism assay [80]. The binding 
mode of this series is illustrated by a CDK2-compound 2 complex structure (Kd 300 nM).  
In this structure, the hydroxyphenyl moiety of the inhibitor binds to the hinge, the DFG 
motif is in the “in” conformation, and a quinolone 3-chlorophenyl group sits in a 
hydrophobic pocket under the C-helix.  Occupation of this pocket translates and rotates 
the C-helix into a position incompatible with cyclin association (PDB 4NJ3, Figure 8b). 
Inhibitors that block cyclin binding might be expected to exert different cellular effects from 
those that sequester cyclins into an inactive complex.  Whether such differences in activity 
translate into novel therapeutic possibilities awaits the identification of cell active type III 
CDK inhibitors. 
Conclusions  
As surveyed above, a range of structural properties have reportedly been exploited to 
maximise selective inhibition of CDK family members. These properties can be grouped 
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into categories as follows: i) relating to unique or less common sequence features 
(including residues that may be exploited for irreversible inhibition, residues that flank the 
cofactor binding site, gatekeeper residues, and residues of the C-terminal tail of 
transcriptional CDKs), ii) relating to uncommon conformations that can be accessed by 
loops and residues that line the active site of CDK family members (including the P-loop, 
the DFG motif, and the C-terminal tail of transcriptional CDKs), and iii) relating to the more 
diverse structural properties and increased plasticity of the cyclin-free forms of the 
enzymes. As applies with any categorization, the groupings identified here are blurred in 
places: sequence differences within the CDK hinge can apparently be read out by 
inhibitors that don’t contact the sidechains directly, a source of selectivity that could be 
categorized under heading (i) or heading (ii). In practice, however, selective inhibition is 
likely to derive from a composite of effects, and to be achieved through painstaking 
exploration of the static and plastic qualities of each CDK as it responds to the binding of 
different inhibitor series.   
For more general strategies that have not been fully explored to date, maybe the most 
interesting are those that relate to either allosteric modulation, involving binding to sites on 
CDK-cyclin complexes remote from the ATP binding site, and/or exploiting the less well 
conserved structures of monomeric states of CDKs. 
With palbociclib and ribociclib now approved for use in therapy, the tractability of this target 
sub-family is now firmly established, paving the way for further clinical development 
targeting other CDKs. Results suggest that development of all kinase inhibitor types (I 
through IV) may be possible for the CDK sub-family, and have identified static and plastic 
properties of CDKs and their inhibitors which can provide a sufficient degree of selectivity 
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Figure 1. CDK activation 
(a)  Cyclin binding and phosphorylation activate CDKs. A notable exception is CDK8-cyclin 
C where the residue phosphorylated within the activation segment in most CDKs is 
replaced by an aspartate (CDK8 Asp191). Monomeric CDK2 (light blue, PDB 1HCK) is 
superposed on phosphorylated CDK2-cyclin A (CDK2: dark blue ribbon, cyclin A: semi-
transparent surface, PDB 1JST). The CDK2 activation segment is highlighted in green. (b) 
Phosphorylated CDK4 bound to cyclin D1 (PDB 2W96) resembles monomeric CDK2 (light 
blue ribbon, PDB 1HCK). CDK4 and cyclin D1 are represented by an orange ribbon and a 
semi-transparent surface respectively, with the CDK4 activation segment highlighted in 
brown. (c) Sequence alignment over the CDK active site. “Zappo” color coding is used to 
distinguish physicochemical properties [81]. (d) Stereo view of key CDK active site 
residues colored by conservation (green, conserved; red, non-conserved, [82]).  
 
Figure 2. CDK2 ATP-competitive inhibitors explore the active site   
(a) The binding of CDK2 to ATP (PDB 1HCK) is mimicked by inhibitors: (b) CDK2-
dinaciclib (PDB 4KD1), (c) CDK2-cyclin A-NU6102 (PDB 1H1S). Within the CDK family, 
alternative modes of CDK hinge-inhibitor interaction have been observed. (d) CDK5-4a, 
(PDB 4AU8), (e) CDK8-22, (PDB 5CEI) and (f) CDK9-DRB (PDB 3MY1). The CDK5, 
CDK8 and CDK9 folds are colored red, dark green and lilac respectively throughout.    
  
Figure 3. The gatekeeper pocket 
CDK inhibitors that bind through hinge motif make a number of interactions with the 
conserved phenylalanine gatekeeper residue. (a) CDK6-compound 3 (PDB 4EZ5, 
aromatic-aromatic) (b) CDK8- CCT251921 (PDB 5HBJ, aromatic-halogen) (c) CDK8- 
compound 6 (PDB 5ICP, aromatic-sulfur). The CDK6 fold is colored cyan. Dotted lines, 
which elsewhere are used to indicate hydrogen bonds, are used in this panel to indicate 
contacts between the inhibitors and the gatekeeper residue. 
 
Figure 4. The DFG motif and back pocket remodeling 
A comparison of CDK8-cyclin C bound to type II and type I inhibitors (a) CDK8-cyclin C in 
complex with the type II inhibitor sorafenib (PDB 3RGF). (b) CDK8-cyclin C bound to 
cortistatin A (PDB 4CRL). Comparing the figures illustrates how sorafenib binding is 
 21 
incompatible with the DMG-in conformation. (c) DFG-out CDK2 in complex with the type II 
inhibitor K03861 (PDB 5A14). (d) A comparison of CDK2-cyclin A bound to roscovitine in a 
DFG-in conformation (ice blue, PDB 3DDQ) again illustrates how a type II inhibitor binding 
is incompatible with a CDK2 DFG-in conformation.  
 
Figure 5. The ATP ribose phosphate binding pocket 
(a) An overlay of CDK structures illustrates the dynamic nature of the glycine-rich loop. 
CDKs are colored as previously. CDKs 4, 7 and 12 are colored orange, magenta and white 
respectively. (b) The CDK5 glycine-rich loop is restructured upon binding (R)-roscovitine 
(PDB 1UNL, crimson). The structure of CDK5-(R)-roscovitine is overlaid with CDK2-(R)-
roscovitine (PDB 3DDQ, light blue) and CDK2-cyclinA (PDB entry 1FIN, glycine-loop 
colored green).  (c) Comparison of inhibitor 12u binding to CDK2 (PDB 4BCP, CDK2 light 
blue 12u yellow) and CDK9 (PDB 4BCG, CDK9 lilac and 12u green) illustrates local 
conformational flexibility around the CDK9 active site can drive compound selectivity. (d) 
Comparison of CDK9-cyclin T bound to a more diverse inhibitor set reveals significant 
movements of the glycine-rich loop and also of the beta3-alphaC loop (PDBs 3BLQ, 3BLR, 
3LQ5, 3MY1, 3TN8, 4BCG). 
 
Figure 6.  CDK-selective inhibitors exploit sequence differences on the surface of 
the CDK C-terminal lobe 
(a) Monomeric CDK6 bound to clinical candidate palbociclib (PDB 5L2I), (b) CDK6 bound 
to ribociclib (PDB 5L2T). (c) CDK2-cyclin A bound to NU6102 (PDB 1H1S). The structures 
illustrate selectivity between CDK2 and CDK6 through interactions of Lys89 and Thr107 
respectively. (d) CDK9 has a glycine residue (Gly112) at the equivalent position, illustrated 
in the structure of CDK9-cyclin T bound to compound 4 (PDB 4BCH). 
 
Figure 7.  The impact of the C-terminal tail on the catalytic cleft in the transcriptional 
CDKs. 
The transcriptional CDKs are characterized by extended C-terminal sequences beyond the 
conserved kinase domain, emerging data shows how the C-terminal tail can impact the 
character of the ATP binding site. (a)  CDK9 structure bound to DRB (PDB 3MYC) overlaid 
with full-length CDK9 (PDB 4EC8). (b) The CDK8 tail also reaches up into the active site 
as illustrated by the structure of the CDK8-CCT251545 complex. There is a favorable 
cation-pi interaction between the phenyl ring of the inhibitor and the guanidine moiety of 
 22 
Arg356 (PDB entry 5BNJ). (c) Similar trapping of the inhibitor THZ531 through the 
formation of an irreversible bond with Cys1039 located within the CDK12 C-terminal 
extension, as observed in the structure of a CDK12-cyclin K-THZ531 complex (PDB 
5ACB). 
 
Figure 8.  Targeting the monomeric enzyme 
(a) ANS bound to an allosteric site adjacent to the ATP site, the structural rearrangement 
creates a large pocket that accommodated two ANS molecules. The shift in the C-helix 
position was predicted to be incompatible with cyclin binding (PDB entry 3PXQ). (b) 
Structure of CDK2 bound to type I ½ quinolone-based inhibitor (compound 14) in which a 
phenol hydroxyl binds to the hinge, the DFG motif is in the “in” conformation and the 
quinolone 3-chlorophenyl group sits in a hydrophobic pocket under the C-helix that 
displaces it out by a translation and rotation to a position incompatible with cyclin 





Residues numbers based on CDK2
10 18 33 51 85 86 88 89 131 132 134 145
CDK1 I V K E M D K K Q N L D
CDK2 I V K E Q D K K Q N L D
CDK4 I V K E Q D R T E N L D
CDK6 I V K E Q D T T Q N L D
CDK8 V V K E H D W H A N L D
CDK9 I V K E H D A G A N L D
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